Invectys, Inc. Announces Presentation of First-in-Human Clinical Trial Design on HLA-G–Targeted CAR T Therapy at ASCO 2025
Houston, TX – May 28, 2025 – Invectys, Inc., a clinical-stage biotechnology company pioneering novel cancer immunotherapies, announced today that MD Anderson Investigators Drs. Samer Srour and Aung Naing will present a Trial-in-Progress poster at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 30–June 3 in Chicago, Illinois.
The presentation will detail the ongoing Phase 1/2a clinical trial evaluating IVS-3001, Invectys’ first-in-human chimeric antigen receptor (CAR) T-cell therapy targeting HLA-G, a non-classical MHC class I molecule overexpressed in various solid tumors. HLA-G functions as a powerful immune checkpoint, enabling tumor cells to evade immune surveillance. By engineering CAR T cells to recognize and eliminate HLA-G–expressing cancer cells, IVS-3001 aims to restore the immune system’s ability to combat tumors.
Presentation Details:
- Abstract Title: Safety and efficacy of HLA-G–targeted CAR T cells (IVS-3001) in patients with advanced HLA-G–positive solid tumors: Clinical trial in progress
- Abstract Number: TPS2679
- Session: Developmental Therapeutics—Immunotherapy
- Session Type: Poster Session
- Poster Board Number: 320b
- Date and Time: Monday, June 2, 2025, 1:30 PM – 4:30 PM CDT
- Location: McCormick Place Convention Center, Chicago, IL
The Phase 1/2a trial is designed to assess the safety, tolerability, and preliminary efficacy of IVS-3001 in patients with advanced solid tumors expressing HLA-G. The study also aims to evaluate the therapy’s pharmacokinetics and immunogenicity.
“We are excited to share our progress on IVS-3001 at ASCO 2025. Patients with solid tumors have profound unmet clinical need. HLA-G is an especially exciting target for cell therapy, as it is both a widely expressed tumor marker and a potent immune checkpoint. Thus, HLA-G directed therapies have the potential to treat a vast variety of solid tumors.” said Dr. Jake Kushner, CEO of Invectys. “This study represents a key step forward in our mission to develop innovative immunotherapies that address unmet needs in oncology.”
About Invectys
Inspired by ideas from the world-renowned Pasteur Institute in Paris, Invectys, Inc. has two wholly owned subsidiaries, Invectys, S.A.S (Paris), which is focused on scientific research and innovation and Invectys USA, Inc. (Houston), whose lead product is the development of a first-in-human anti-HLA-G CAR T therapy. Invectys USA, Inc. has received a grant of $14.2 million from the Cancer Prevention and Research Institute of Texas (grant number DP200034) to help fund its HLA-G CAR-T program.
About IVS–3001
IVS-3001 is an HLA-G-targeting, 3rd generation chimeric antigen receptor (CAR) T cell therapy. HLA-G is not only an immune checkpoint but also a tumor-specific antigen that is widely expressed in a large variety of solid tumors. HLA-G is exceptionally valuable as a target for CAR T therapy as it is highly tumor specific, with minimal expression in healthy tissues except in placenta. In this regard, the Invectys HLA-G CAR T strategy addresses two key knowledge gaps for cell therapies for solid tumors: the Invectys CAR construct consists of the HLA-G antigen-targeting domain fused to intracellular signaling domains. The CAR allows IVS-3001 to recognize and kill target cells which express HLA-G on the cell surface. Antigen-specific activation of IVS-3001 results in CAR T cell proliferation, cytokine secretion, and subsequent cytolytic killing of HLA-G-expressing cells.
